Biopharmaceutical company developing therapies to treat autoimmune diseases.
Aurinia Pharmaceuticals Inc. is a dynamic biopharmaceutical company operating at the forefront of commercial-stage development, dedicated to advancing therapies for a range of diseases with significant unmet medical needs across the United States. Central to its portfolio is LUPKYNIS, a groundbreaking treatment specifically designed for adult patients suffering from active lupus nephritis, a severe and debilitating condition affecting the kidneys.
In addition to its innovative therapies, Aurinia Pharmaceuticals has forged a strategic collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., enhancing its global reach and capabilities in delivering impactful solutions to patients worldwide. This collaboration underscores Aurinia's commitment to leveraging strategic partnerships to drive advancements in treatment options and expand its therapeutic footprint.
Headquartered in Victoria, Canada, Aurinia Pharmaceuticals is strategically positioned within the vibrant biopharmaceutical hub of North America. The company's location in British Columbia facilitates its access to world-class research and development resources, fostering a culture of innovation and excellence.
With a strong commitment to scientific rigor and patient-centered innovation, Aurinia Pharmaceuticals continues to push boundaries in biopharmaceutical research. By focusing on areas of significant unmet medical need, the company aims to transform the treatment landscape and improve outcomes for patients battling serious and complex diseases.